Inhibrx Biosciences, Inc. INBX Financial Statement Data


2025 Q2

Submissions

Field Row 1 Row 2
adsh 0002007919-25-000056 0002007919-25-000051
cik 2007919 2007919
name INHIBRX BIOSCIENCES, INC. INHIBRX BIOSCIENCES, INC.
sic 2836 2836
countryba US US
stprba CA CA
cityba LA JOLLA LA JOLLA
zipba 92037 92037
bas1 11025 N. TORREY PINES ROAD, SUITE 140 11025 N. TORREY PINES ROAD, SUITE 140
bas2
baph (858) 795-4220 (858) 795-4220
countryma US US
stprma CA CA
cityma LA JOLLA LA JOLLA
zipma 92037 92037
mas1 11025 N. TORREY PINES ROAD, SUITE 140 11025 N. TORREY PINES ROAD, SUITE 140
mas2
countryinc US US
stprinc DE DE
ein 990613523 990613523
former IBEX SPINCO, INC. IBEX SPINCO, INC.
changed 20240111 20240111
afs 4-NON 4-NON
wksi 0 0
fye 1231 1231
form 10-Q POS AM
period 20250331 20241231
fy 2025
fp Q1
filed 20250514 20250417
accepted 2025-05-14 16:09:00.0 2025-04-17 16:05:00.0
prevrpt 0 0
detail 1 1
instance inhibrx-20250331_htm.xml inhibrx-20250417_htm.xml
nciks 1 1
aciks

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
cik Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings.
name Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date.
sic Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business.
countryba The ISO 3166-1 country of the registrant's business address.
stprba The state or province of the registrant’s business address, if field countryba is US or CA.
cityba The city of the registrant's business address.
zipba The zip code of the registrant’s business address.
bas1 The first line of the street of the registrant’s business address.
bas2 The second line of the street of the registrant’s business address.
baph The phone number of the registrant’s business address.
countryma The ISO 3166-1 country of the registrant's mailing address.
stprma The state or province of the registrant’s mailing address, if field countryma is US or CA.
cityma The city of the registrant's mailing address.
zipma The zip code of the registrant’s mailing address.
mas1 The first line of the street of the registrant’s mailing address.
mas2 The second line of the street of the registrant’s mailing address.
countryinc The ISO 3166-1 country of incorporation for the registrant.
stprinc The state or province of incorporation for the registrant, if countryinc is US or CA.
ein Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States.
former Most recent former name of the registrant, if any.
changed Date of change from the former name, if any.
afs Filer status with the SEC at the time of submission:
1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned.
wksi Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement.
fye Fiscal Year End Date, rounded to nearest month-end.
form The submission type of the registrant’s filing.
period Balance Sheet Date, rounded to nearest month-end.
fy Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8).
fp Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year.
filed The date of the registrant’s filing with the Commission.
accepted The acceptance date and time of the registrant’s filing with the Commission.
prevrpt Previous Report – TRUE indicates that the submission information was subsequently amended.
detail TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount).
instance The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol.
nciks Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing.
aciks Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information.

Numbers

adsh ddate tag value uom qtrs version segments coreg footnote
0002007919-25-000051 20241231 Operating Expenses 331648000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20241231 Operating Lease Right Of Use Asset 7338000.0000 USD 0 us-gaap/2024
0002007919-25-000051 20241231 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 58518000.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0002007919-25-000051 20241231 Cash And Cash Equivalents At Carrying Value 152596000.0000 USD 0 us-gaap/2024
0002007919-25-000051 20241231 Gain Loss On Sale Of Property Plant Equipment -12000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20231231 Increase Decrease In Other Noncurrent Assets 0.0000 USD 4 us-gaap/2024
0002007919-25-000051 20241231 Increase Decrease In Other Noncurrent Assets 3667000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20241231 Net Cash Provided By Used In Financing Activities 71678000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20241231 Net Cash Provided By Used In Operating Activities -194409000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20231231 Net Income Loss -241361000.0000 USD 4 us-gaap/2024 Business Segments= Reportable Segment;
0002007919-25-000051 20241231 Net Income Loss 1687572000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20241231 Net Income Loss 1687572000.0000 USD 4 us-gaap/2024 Business Segments= Reportable Segment;
0002007919-25-000051 20231231 Nonmonetary Transaction Gain Loss Recognized On Transfer 0.0000 USD 4 us-gaap/2024
0002007919-25-000051 20241231 Nonmonetary Transaction Gain Loss Recognized On Transfer 68000000.0000 USD 4 us-gaap/2024 Nonmonetary Transaction Type= Transaction Costs Paid By Acquirer;
0002007919-25-000051 20231231 Operating Expenses 221021000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20231231 Other Assets Noncurrent 3164000.0000 USD 0 us-gaap/2024
0002007919-25-000051 20241231 Other Assets Noncurrent 6831000.0000 USD 0 us-gaap/2024
0002007919-25-000051 20241231 Other Noncash Income 0.0000 USD 4 us-gaap/2024
0002007919-25-000051 20231231 Preferred Stock Value 0.0000 USD 0 us-gaap/2024
0002007919-25-000051 20241231 Preferred Stock Value 0.0000 USD 0 us-gaap/2024
0002007919-25-000051 20241231 Research And Development Expense 203743000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20231231 Revenues 1634000.0000 USD 4 us-gaap/2024 Major Customers= Phylaxis Bio Science L L C; Product Or Service= License Non Affiliate;
0002007919-25-000051 20231231 Stockholders Equity -613734000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0002007919-25-000051 20241231 Stockholders Equity Note Spinoff Transaction -5000.0000 USD 4 us-gaap/2024 Equity Components= Common Stock;
0002007919-25-000051 20241231 Stock Issued During Period Shares Conversion Of Convertible Securities 2746000.0000 shares 4 us-gaap/2024 Equity Components= Common Stock;
0002007919-25-000051 20241231 Stock Issued During Period Value Stock Options Exercised 71678000.0000 USD 4 us-gaap/2024
0002007919-25-000056 20250331 Accounts Receivable Net Current 214000.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Nonrelated Party;
0002007919-25-000056 20250331 Accounts Receivable Net Current 0.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Related Party;
0002007919-25-000056 20241231 Accrued Liabilities Current 29890000.0000 USD 0 us-gaap/2024
0002007919-25-000056 20250331 Capital Expenditures Incurred But Not Yet Paid 0.0000 USD 1 us-gaap/2024
0002007919-25-000056 20240531 Common Stock Shares Outstanding 14475904.0000 shares 0 us-gaap/2024
0002007919-25-000056 20241231 Common Stock Shares Outstanding 14476000.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0002007919-25-000056 20250331 Depreciation Depletion And Amortization 588000.0000 USD 1 us-gaap/2024 Income Statement Location= Research And Development Expense;
0002007919-25-000056 20250331 Earnings Per Share Basic -2.8000 USD 1 us-gaap/2024
0002007919-25-000056 20250331 General And Administrative Expense 6024000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20250331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest -43311000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20240331 Income Taxes Paid Net 0.0000 USD 1 us-gaap/2024
0002007919-25-000056 20240331 Net Cash Provided By Used In Financing Activities 38728000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20240331 Net Cash Provided By Used In Operating Activities -63050000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20250331 Net Income Loss -43311000.0000 USD 1 us-gaap/2024 Equity Components= Retained Earnings;
0002007919-25-000056 20250331 Noncash Operating Lease Expense 434000.0000 USD 1 0002007919-25-000056
0002007919-25-000056 20241231 Operating Lease Liability Current 1595000.0000 USD 0 us-gaap/2024
0002007919-25-000056 20240331 Other Nonoperating Income Expense -4885000.0000 USD 1 us-gaap/2024 Business Segments= Reportable Segment;
0002007919-25-000056 20240331 Payments Of Debt Issuance Costs Secured Debt 0.0000 USD 1 0002007919-25-000056
0002007919-25-000056 20250331 Preferred Stock Shares Outstanding 0.0000 shares 0 us-gaap/2024
0002007919-25-000056 20250331 Prepaid Expense And Other Assets Current 6652000.0000 USD 0 us-gaap/2024
0002007919-25-000056 20240331 Proceeds From Stock Options Exercised 38728000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20241231 Retained Earnings Accumulated Deficit -106132000.0000 USD 0 us-gaap/2024
0002007919-25-000056 20250331 Share Based Compensation 0.0000 USD 1 us-gaap/2024 Plan Name= A2017 Plan;
0002007919-25-000056 20241231 Stockholders Equity 133584000.0000 USD 0 us-gaap/2024
0002007919-25-000056 20241231 Stockholders Equity 1000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0002007919-25-000056 20240331 Stock Issued During Period Value Stock Options Exercised 40378000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20240331 Stock Issued During Period Value Stock Options Exercised 40378000.0000 USD 1 us-gaap/2024 Equity Components= Additional Paid In Capital;
0002007919-25-000051 20241231 Common Stock Shares Issued 14475904.0000 shares 0 us-gaap/2024
0002007919-25-000051 20231231 Accounts Receivable Net Current 0.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Related Party;
0002007919-25-000051 20231231 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 24846000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20231231 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 24846000.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0002007919-25-000051 20231231 Assets Current 295358000.0000 USD 0 us-gaap/2024
0002007919-25-000051 20231231 Common Stock Shares Outstanding 47369000.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0002007919-25-000051 20241231 Depreciation Depletion And Amortization 404000.0000 USD 4 us-gaap/2024 Income Statement Location= General And Administrative Expense;
0002007919-25-000051 20231231 Income Loss From Equity Method Investments -1634000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20231231 Increase Decrease In Accounts Receivable 535000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20231231 Increase Decrease In Operating Lease Liability -1860000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20231231 Interest Income Nonoperating 11917000.0000 USD 4 0002007919-25-000051
0002007919-25-000051 20241231 Liabilities And Stockholders Equity 180767000.0000 USD 0 us-gaap/2024
0002007919-25-000051 20231231 Net Income Loss -241361000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20241231 Nonmonetary Transaction Gain Loss Recognized On Transfer 1727687000.0000 USD 4 us-gaap/2024 Nonmonetary Transaction Type= Merger Consideration;
0002007919-25-000051 20231231 Other Noncash Income 1634000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20241231 Preferred Stock Shares Authorized 15000000.0000 shares 0 us-gaap/2024
0002007919-25-000051 20241231 Retained Earnings Accumulated Deficit -106132000.0000 USD 0 us-gaap/2024
0002007919-25-000051 20231231 Revenues 1800000.0000 USD 4 us-gaap/2024 Product Or Service= License Non Affiliate;
0002007919-25-000051 20241231 Revenues 0.0000 USD 4 us-gaap/2024 Major Customers= Phylaxis Bio Science L L C; Product Or Service= License Non Affiliate;
0002007919-25-000051 20241231 Revenues 200000.0000 USD 4 us-gaap/2024 Product Or Service= License Non Affiliate;
0002007919-25-000051 20231231 Stock And Pre Funded Warrants Issued During Period Value 1000.0000 USD 4 0002007919-25-000051 Equity Components= Common Stock;
0002007919-25-000051 20221231 Stockholders Equity 58057000.0000 USD 0 us-gaap/2024
0002007919-25-000051 20231231 Stockholders Equity 657232000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0002007919-25-000051 20241231 Stockholders Equity -106132000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0002007919-25-000051 20240630 Stock Issued During Period Shares Conversion Of Convertible Securities 2746454.0000 shares 1 us-gaap/2024
0002007919-25-000051 20241231 Stock Issued During Period Value Stock Options Exercised 71678000.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0002007919-25-000056 20250331 Accounts Payable Current 8892000.0000 USD 0 us-gaap/2024
0002007919-25-000056 20250331 Assets 242639000.0000 USD 0 us-gaap/2024
0002007919-25-000056 20250331 Commitments And Contingencies USD 0 us-gaap/2024
0002007919-25-000056 20250331 Common Stock Shares Outstanding 14475904.0000 shares 0 us-gaap/2024
0002007919-25-000056 20250331 Depreciation Depletion And Amortization 675000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20240331 Increase Decrease In Accrued Liabilities 8034000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20240331 Increase Decrease In Other Receivables 610000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20250331 Nonoperating Income Expense -410000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20250331 Operating Expenses 42901000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20240331 Operating Income Loss -73825000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20250331 Operating Lease Liability Current 1973000.0000 USD 0 us-gaap/2024
0002007919-25-000056 20241231 Operating Lease Right Of Use Asset 7338000.0000 USD 0 us-gaap/2024
0002007919-25-000056 20250331 Operating Lease Right Of Use Asset 6904000.0000 USD 0 us-gaap/2024
0002007919-25-000056 20240331 Payments To Acquire Property Plant And Equipment 1119000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20250331 Retained Earnings Accumulated Deficit -149443000.0000 USD 0 us-gaap/2024
0002007919-25-000056 20240331 Share Based Compensation 6397000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20240331 Stockholders Equity 704007000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0002007919-25-000051 20231231 Amortization Of Financing Costs And Discounts 4899000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20231231 Cash And Cash Equivalents At Carrying Value 277924000.0000 USD 0 us-gaap/2024
0002007919-25-000051 20240531 Common Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024
0002007919-25-000051 20231231 Common Stock Shares Authorized 120000000.0000 shares 0 us-gaap/2024
0002007919-25-000051 20240531 Common Stock Shares Outstanding 14475904.0000 shares 0 us-gaap/2024
0002007919-25-000051 20241231 Common Stock Shares Outstanding 14475904.0000 shares 0 us-gaap/2024
0002007919-25-000051 20241231 Common Stock Shares Outstanding 14476000.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0002007919-25-000051 20231231 Common Stock Value 5000.0000 USD 0 us-gaap/2024
0002007919-25-000051 20241231 Depreciation Depletion And Amortization 1881000.0000 USD 4 us-gaap/2024 Income Statement Location= Research And Development Expense;
0002007919-25-000051 20231231 Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments -239724000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20231231 Income Tax Expense Benefit 3000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20231231 Increase Decrease In Accounts Payable 2109000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20241231 Increase Decrease In Accounts Receivable -381000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20231231 Increase Decrease In Accrued Liabilities 26071000.0000 USD 4 us-gaap/2024
0002007919-25-000056 20241231 Common Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024
0002007919-25-000056 20250331 Common Stock Shares Authorized 120000000.0000 shares 0 us-gaap/2024
0002007919-25-000056 20241231 Common Stock Shares Outstanding 14475904.0000 shares 0 us-gaap/2024
0002007919-25-000051 20241231 Increase Decrease In Operating Lease Liability -1408000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20241231 Liabilities 47183000.0000 USD 0 us-gaap/2024
0002007919-25-000051 20231231 Liabilities And Stockholders Equity 307893000.0000 USD 0 us-gaap/2024
0002007919-25-000051 20231231 Net Cash Provided By Used In Investing Activities -4593000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20241231 Noncash Operating Lease Expense 1897000.0000 USD 4 0002007919-25-000051
0002007919-25-000051 20231231 Operating Income Loss -219221000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20241231 Operating Lease Liability Noncurrent 6453000.0000 USD 0 us-gaap/2024
0002007919-25-000051 20231231 Preferred Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024
0002007919-25-000051 20231231 Preferred Stock Shares Authorized 15000000.0000 shares 0 us-gaap/2024
0002007919-25-000051 20241231 Prepaid Expense And Other Assets Current 7382000.0000 USD 0 us-gaap/2024
0002007919-25-000051 20231231 Proceeds From Stock Options Exercised 2316000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20241231 Share Based Compensation 58518000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20231231 Stock And Pre Funded Warrants Issued During Period Value 199644000.0000 USD 4 0002007919-25-000051 Equity Components= Additional Paid In Capital;
0002007919-25-000051 20241231 Stockholder Equity Spinoff Transaction Decrease In Common Stock 53564000.0000 shares 4 0002007919-25-000051 Equity Components= Common Stock;
0002007919-25-000051 20221231 Stockholders Equity 4000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0002007919-25-000051 20241231 Stock Issued During Period Value New Issues 16042000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20241231 Weighted Average Number Of Shares Outstanding Basic 14802000.0000 shares 4 us-gaap/2024
0002007919-25-000056 20240331 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 6397000.0000 USD 1 us-gaap/2024 Equity Components= Additional Paid In Capital;
0002007919-25-000056 20240331 Capital Expenditures Incurred But Not Yet Paid 307000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20241231 Cash And Cash Equivalents At Carrying Value 152596000.0000 USD 0 us-gaap/2024
0002007919-25-000056 20250331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 216520000.0000 USD 0 us-gaap/2024
0002007919-25-000056 20241231 Commitments And Contingencies USD 0 us-gaap/2024
0002007919-25-000056 20240331 Depreciation Depletion And Amortization 256000.0000 USD 1 us-gaap/2024 Income Statement Location= Research And Development Expense;
0002007919-25-000056 20240331 General And Administrative Expense 9974000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20240331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest -78710000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20250331 Income Tax Expense Benefit 0.0000 USD 1 us-gaap/2024
0002007919-25-000056 20240331 Increase Decrease In Other Noncurrent Assets 1422000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20250331 Increase Decrease In Other Noncurrent Assets -28000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20250331 Interest Expense Nonoperating 2689000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20250331 Interest Income Nonoperating 2329000.0000 USD 1 0002007919-25-000056
0002007919-25-000056 20240331 Interest Paid Net 6892000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20241231 Liabilities 47183000.0000 USD 0 us-gaap/2024
0002007919-25-000056 20240331 Net Income Loss -78710000.0000 USD 1 us-gaap/2024 Business Segments= Reportable Segment;
0002007919-25-000056 20250331 Net Income Loss -43311000.0000 USD 1 us-gaap/2024 Business Segments= Reportable Segment;
0002007919-25-000056 20241231 Other Assets Noncurrent 6831000.0000 USD 0 us-gaap/2024
0002007919-25-000056 20250331 Other Assets Noncurrent 6803000.0000 USD 0 us-gaap/2024
0002007919-25-000056 20250331 Preferred Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024
0002007919-25-000056 20250331 Preferred Stock Shares Authorized 15000000.0000 shares 0 us-gaap/2024
0002007919-25-000056 20250331 Preferred Stock Shares Issued 0.0000 shares 0 us-gaap/2024
0002007919-25-000056 20250331 Preferred Stock Value 0.0000 USD 0 us-gaap/2024
0002007919-25-000056 20250331 Receivable For Proceeds From The Exercise Of Stock Options 0.0000 USD 1 0002007919-25-000056
0002007919-25-000056 20250331 Share Based Compensation 2450000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20231231 Stockholders Equity -613734000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0002007919-25-000056 20240331 Stockholders Equity 11568000.0000 USD 0 us-gaap/2024
0002007919-25-000056 20240331 Stockholders Equity 5000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0002007919-25-000056 20240331 Stock Issued During Period Shares Stock Options Exercised 1865000.0000 shares 1 us-gaap/2024 Equity Components= Common Stock;
0002007919-25-000056 20250331 Weighted Average Number Of Shares Outstanding Basic 15468000.0000 shares 1 us-gaap/2024
0002007919-25-000051 20241231 Commitments And Contingencies USD 0 us-gaap/2024
0002007919-25-000051 20231231 Accounts Payable Current 10954000.0000 USD 0 us-gaap/2024
0002007919-25-000051 20241231 Capital Expenditures Incurred But Not Yet Paid 0.0000 USD 4 us-gaap/2024
0002007919-25-000051 20241231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 152596000.0000 USD 0 us-gaap/2024
0002007919-25-000051 20231231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect 4059000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20241231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect -125328000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20231231 Commitments And Contingencies USD 0 us-gaap/2024
0002007919-25-000051 20240531 Common Stock Shares Authorized 120000000.0000 shares 0 us-gaap/2024
0002007919-25-000051 20231231 Depreciation Depletion And Amortization 992000.0000 USD 4 us-gaap/2024 Income Statement Location= Research And Development Expense;
0002007919-25-000051 20241231 Earnings Per Share Diluted 112.6200 USD 4 us-gaap/2024
0002007919-25-000051 20241231 Income Loss From Equity Method Investments 0.0000 USD 4 us-gaap/2024
0002007919-25-000051 20241231 Income Taxes Paid Net 2000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20231231 Increase Decrease In Prepaid Deferred Expense And Other Assets 10285000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20241231 Interest Expense Nonoperating 13491000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20241231 Liabilities Current 40730000.0000 USD 0 us-gaap/2024
0002007919-25-000051 20231231 Long Term Debt Noncurrent 206968000.0000 USD 0 us-gaap/2024
0002007919-25-000051 20241231 Nonmonetary Transaction Gain Loss Recognized On Transfer 14496000.0000 USD 4 us-gaap/2024 Nonmonetary Transaction Type= Net Assets And Liabilities Assumed By Acquirer;
0002007919-25-000051 20241231 Operating Income Loss -331448000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20231231 Operating Lease Liability Noncurrent 1110000.0000 USD 0 us-gaap/2024
0002007919-25-000051 20241231 Other Nonoperating Income Expense 2019022000.0000 USD 4 us-gaap/2024 Business Segments= Reportable Segment;
0002007919-25-000051 20231231 Preferred Stock Shares Outstanding 0.0000 shares 0 us-gaap/2024
0002007919-25-000051 20241231 Preferred Stock Shares Outstanding 0.0000 shares 0 us-gaap/2024
0002007919-25-000051 20231231 Property Plant And Equipment Net 6419000.0000 USD 0 us-gaap/2024
0002007919-25-000051 20241231 Remeasurement Of Operating Lease Liability And Right Of Use Asset In Connection With2024 Lease Agreement 6283000.0000 USD 4 0002007919-25-000051
0002007919-25-000051 20231231 Research And Development Expense 191640000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20231231 Retained Earnings Accumulated Deficit -613734000.0000 USD 0 us-gaap/2024
0002007919-25-000051 20231231 Revenues 1800000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20231231 Revenues 0.0000 USD 4 us-gaap/2024 Major Customers= Regeneron Pharmaceuticals Inc.; Product Or Service= License Non Affiliate;
0002007919-25-000051 20241231 Revenues 200000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20231231 Stockholders Equity 43503000.0000 USD 0 us-gaap/2024
0002007919-25-000051 20231231 Stockholders Equity 5000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0002007919-25-000051 20241231 Stock Issued During Period Value New Issues 16041000.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0002007919-25-000051 20241231 Stock Issued During Period Value New Issues 1000.0000 USD 4 us-gaap/2024 Equity Components= Common Stock;
0002007919-25-000051 20241231 Weighted Average Number Of Diluted Shares Outstanding 14984000.0000 shares 4 us-gaap/2024
0002007919-25-000051 20231231 Weighted Average Number Of Shares Outstanding Basic 11783000.0000 shares 4 us-gaap/2024
0002007919-25-000056 20241231 Accounts Receivable Net Current 397000.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Nonrelated Party;
0002007919-25-000056 20250331 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 2450000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20250331 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 2450000.0000 USD 1 us-gaap/2024 Equity Components= Additional Paid In Capital;
0002007919-25-000056 20250331 Adjustments To Additional Paid In Capital Warrant Issued 1700000.0000 USD 1 us-gaap/2024 Longterm Debt Type= Secured Debt;
0002007919-25-000056 20241231 Assets Current 160398000.0000 USD 0 us-gaap/2024
0002007919-25-000056 20240531 Common Stock Shares Authorized 120000000.0000 shares 0 us-gaap/2024
0002007919-25-000056 20240531 Common Stock Shares Issued 13316140.0000 shares 0 us-gaap/2024
0002007919-25-000056 20240331 Common Stock Shares Outstanding 49234000.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0002007919-25-000056 20250331 Common Stock Shares Outstanding 14476000.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0002007919-25-000056 20240331 Depreciation Depletion And Amortization 360000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20240331 Depreciation Depletion And Amortization 104000.0000 USD 1 us-gaap/2024 Income Statement Location= General And Administrative Expense;
0002007919-25-000056 20240331 Earnings Per Share Diluted -5.7700 USD 1 us-gaap/2024
0002007919-25-000056 20250331 Increase Decrease In Accrued Liabilities 2884000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20240331 Interest Expense Nonoperating 8130000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20240331 Interest Income Nonoperating 3304000.0000 USD 1 0002007919-25-000056
0002007919-25-000056 20250331 Interest Paid Net 1299000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20250331 Net Cash Provided By Used In Operating Activities -35895000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20240331 Net Income Loss -78710000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20250331 Operating Income Loss -42901000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20241231 Operating Lease Liability Noncurrent 6453000.0000 USD 0 us-gaap/2024
0002007919-25-000056 20240331 Other Nonoperating Income Expense -59000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20250331 Other Nonoperating Income Expense -410000.0000 USD 1 us-gaap/2024 Business Segments= Reportable Segment;
0002007919-25-000056 20240531 Preferred Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024
0002007919-25-000056 20241231 Preferred Stock Shares Issued 0.0000 shares 0 us-gaap/2024
0002007919-25-000056 20241231 Stockholders Equity 239715000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0002007919-25-000056 20250331 Stockholders Equity -149443000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0002007919-25-000056 20240331 Weighted Average Number Of Shares Outstanding Basic 13639000.0000 shares 1 us-gaap/2024
0002007919-25-000051 20241231 Accounts Receivable Net Current 397000.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Nonrelated Party;
0002007919-25-000051 20231231 Additional Paid In Capital 657232000.0000 USD 0 us-gaap/2024
0002007919-25-000051 20241231 Assets Current 160398000.0000 USD 0 us-gaap/2024
0002007919-25-000051 20221231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 273865000.0000 USD 0 us-gaap/2024
0002007919-25-000051 20241231 Common Stock Shares Authorized 120000000.0000 shares 0 us-gaap/2024
0002007919-25-000051 20231231 Earnings Per Share Basic -20.4800 USD 4 us-gaap/2024
0002007919-25-000051 20231231 Gain Loss On Sale Of Property Plant Equipment -3000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20241231 General And Administrative Expense 127905000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20241231 Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments 1687574000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20241231 Increase Decrease In Accrued Liabilities 35883000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20241231 Increase Decrease In Due From Related Parties 23000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20241231 Interest Paid Net 11506000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20231231 Issuance Of Common Stock And Pre Funded Warrants In Private Placement Net Of Issuance Costs In Common Stock 3621000.0000 shares 4 0002007919-25-000051 Equity Components= Common Stock;
0002007919-25-000051 20231231 Liabilities 264390000.0000 USD 0 us-gaap/2024
0002007919-25-000051 20241231 Nonmonetary Transaction Gain Loss Recognized On Transfer 211315000.0000 USD 4 us-gaap/2024 Nonmonetary Transaction Type= Loans Assumed By Acquirer;
0002007919-25-000051 20241231 Nonoperating Income Expense 2019022000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20231231 Other Nonoperating Income Expense -20503000.0000 USD 4 us-gaap/2024 Business Segments= Reportable Segment;
0002007919-25-000051 20240531 Preferred Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024
0002007919-25-000051 20241231 Preferred Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024
0002007919-25-000051 20241231 Revenues 200000.0000 USD 4 us-gaap/2024 Business Segments= Reportable Segment;
0002007919-25-000051 20241231 Revenues 200000.0000 USD 4 us-gaap/2024 Major Customers= Regeneron Pharmaceuticals Inc.; Product Or Service= License Non Affiliate;
0002007919-25-000051 20231231 Stock And Pre Funded Warrants Issued During Period Value 199645000.0000 USD 4 0002007919-25-000051
0002007919-25-000051 20241231 Stockholders Equity 133584000.0000 USD 0 us-gaap/2024
0002007919-25-000051 20241231 Stockholders Equity 239715000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0002007919-25-000051 20241231 Stockholders Equity 1000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0002007919-25-000051 20241231 Stock Issued During Period Shares New Issues 14476000.0000 shares 4 us-gaap/2024 Equity Components= Common Stock;
0002007919-25-000051 20241231 Stock Issued During Period Shares Stock Options Exercised 3449000.0000 shares 4 us-gaap/2024 Plan Name= Plan2017;
0002007919-25-000056 20250331 Assets Current 223386000.0000 USD 0 us-gaap/2024
0002007919-25-000056 20231231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 277924000.0000 USD 0 us-gaap/2024
0002007919-25-000056 20250331 Common Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024
0002007919-25-000056 20250331 Common Stock Value 1000.0000 USD 0 us-gaap/2024
0002007919-25-000056 20250331 Depreciation Depletion And Amortization 87000.0000 USD 1 us-gaap/2024 Income Statement Location= General And Administrative Expense;
0002007919-25-000056 20250331 Earnings Per Share Diluted -2.8000 USD 1 us-gaap/2024
0002007919-25-000056 20250331 Increase Decrease In Accounts Payable -353000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20240331 Increase Decrease In Accounts Receivable 0.0000 USD 1 us-gaap/2024
0002007919-25-000056 20250331 Liabilities 148196000.0000 USD 0 us-gaap/2024
0002007919-25-000056 20241231 Liabilities Current 40730000.0000 USD 0 us-gaap/2024
0002007919-25-000056 20250331 Net Cash Provided By Used In Financing Activities 99840000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20240331 Net Income Loss -78710000.0000 USD 1 us-gaap/2024 Equity Components= Retained Earnings;
0002007919-25-000056 20240331 Nonoperating Income Expense -4885000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20240331 Operating Expenses 73825000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20250331 Other Nonoperating Income Expense -50000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20241231 Preferred Stock Value 0.0000 USD 0 us-gaap/2024
0002007919-25-000056 20240331 Proceeds From Issuance Of Secured Debt 0.0000 USD 1 us-gaap/2024
0002007919-25-000056 20250331 Proceeds From Issuance Of Secured Debt 99965000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20241231 Property Plant And Equipment Net 6200000.0000 USD 0 us-gaap/2024
0002007919-25-000056 20231231 Stockholders Equity 657232000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0002007919-25-000056 20240331 Stockholders Equity -692444000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0002007919-25-000056 20250331 Stockholders Equity 94443000.0000 USD 0 us-gaap/2024
0002007919-25-000056 20240331 Stock Issued During Period Shares Stock Options Exercised 0.0000 shares 1 us-gaap/2024 Plan Name= A2024 Plan;
0002007919-25-000056 20250331 Stock Issued During Period Shares Stock Options Exercised 0.0000 shares 1 us-gaap/2024 Plan Name= A2024 Plan;
0002007919-25-000051 20241231 Increase Decrease In Contract With Customer Liability 0.0000 USD 4 us-gaap/2024
0002007919-25-000051 20241231 Accounts Receivable Net Current 23000.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Related Party;
0002007919-25-000051 20241231 Accrued Liabilities Current 29890000.0000 USD 0 us-gaap/2024
0002007919-25-000051 20241231 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 58518000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20241231 Assets 180767000.0000 USD 0 us-gaap/2024
0002007919-25-000051 20240531 Common Stock Shares Issued 13316140.0000 shares 0 us-gaap/2024
0002007919-25-000051 20221231 Common Stock Shares Outstanding 43564000.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0002007919-25-000051 20231231 Depreciation Depletion And Amortization 199000.0000 USD 4 us-gaap/2024 Income Statement Location= General And Administrative Expense;
0002007919-25-000051 20241231 Earnings Per Share Basic 114.0100 USD 4 us-gaap/2024
0002007919-25-000051 20231231 General And Administrative Expense 29381000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20231231 Income Taxes Paid Net 3000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20241231 Income Tax Expense Benefit 2000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20231231 Increase Decrease In Contract With Customer Liability -166000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20241231 Increase Decrease In Prepaid Deferred Expense And Other Assets -2982000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20231231 Liabilities Current 56312000.0000 USD 0 us-gaap/2024
0002007919-25-000051 20231231 Net Cash Provided By Used In Financing Activities 201961000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20241231 Net Cash Provided By Used In Investing Activities -2597000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20241231 Net Income Loss 1687572000.0000 USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0002007919-25-000051 20241231 Nonmonetary Transaction Gain Loss Recognized On Transfer 2021498000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20231231 Nonoperating Income Expense -20503000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20241231 Payments To Acquire Property Plant And Equipment 2597000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20231231 Prepaid Expense And Other Assets Current 16656000.0000 USD 0 us-gaap/2024
0002007919-25-000051 20241231 Proceeds From Issuance Of Private Placement 0.0000 USD 4 us-gaap/2024
0002007919-25-000051 20241031 Remeasurement Of Operating Lease Liability And Right Of Use Asset In Connection With2024 Lease Agreement 6300000.0000 USD 0 0002007919-25-000051
0002007919-25-000051 20231231 Revenues 1800000.0000 USD 4 us-gaap/2024 Product Or Service= License;
0002007919-25-000051 20241231 Revenues 200000.0000 USD 4 us-gaap/2024 Product Or Service= License;
0002007919-25-000051 20221231 Stockholders Equity 430426000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0002007919-25-000051 20241231 Stockholders Equity Note Spinoff Transaction -1743729000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20241231 Stock Issued During Period Shares Stock Options Exercised 3449000.0000 shares 4 us-gaap/2024 Equity Components= Common Stock;
0002007919-25-000051 20231231 Weighted Average Number Of Diluted Shares Outstanding 11783000.0000 shares 4 us-gaap/2024
0002007919-25-000056 20250331 Accrued Liabilities Current 32774000.0000 USD 0 us-gaap/2024
0002007919-25-000056 20241231 Additional Paid In Capital 239715000.0000 USD 0 us-gaap/2024
0002007919-25-000056 20250331 Adjustments To Additional Paid In Capital Warrant Issued 1720000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20250331 Adjustments To Additional Paid In Capital Warrant Issued 1720000.0000 USD 1 us-gaap/2024 Equity Components= Additional Paid In Capital;
0002007919-25-000056 20250331 Cash And Cash Equivalents At Carrying Value 216520000.0000 USD 0 us-gaap/2024
0002007919-25-000056 20240331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 252483000.0000 USD 0 us-gaap/2024
0002007919-25-000056 20240331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect -25441000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20250331 Common Stock Shares Issued 14475904.0000 shares 0 us-gaap/2024
0002007919-25-000056 20241231 Common Stock Value 1000.0000 USD 0 us-gaap/2024
0002007919-25-000056 20240331 Earnings Per Share Basic -5.7700 USD 1 us-gaap/2024
0002007919-25-000056 20240331 Income Tax Expense Benefit 0.0000 USD 1 us-gaap/2024
0002007919-25-000056 20240331 Increase Decrease In Accounts Payable 4050000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20240331 Increase Decrease In Due From Related Parties 0.0000 USD 1 us-gaap/2024
0002007919-25-000056 20240331 Increase Decrease In Operating Lease Liability -495000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20250331 Increase Decrease In Other Receivables 0.0000 USD 1 us-gaap/2024
0002007919-25-000056 20250331 Liabilities And Stockholders Equity 242639000.0000 USD 0 us-gaap/2024
0002007919-25-000056 20250331 Liabilities Current 43639000.0000 USD 0 us-gaap/2024
0002007919-25-000056 20241231 Long Term Debt Noncurrent 0.0000 USD 0 us-gaap/2024
0002007919-25-000056 20250331 Long Term Debt Noncurrent 98653000.0000 USD 0 us-gaap/2024
0002007919-25-000056 20240331 Noncash Operating Lease Expense 465000.0000 USD 1 0002007919-25-000056
0002007919-25-000056 20250331 Payments To Acquire Property Plant And Equipment 21000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20241231 Preferred Stock Shares Outstanding 0.0000 shares 0 us-gaap/2024
0002007919-25-000056 20250331 Proceeds From Stock Options Exercised 0.0000 USD 1 us-gaap/2024
0002007919-25-000056 20240331 Receivable For Proceeds From The Exercise Of Stock Options 1650000.0000 USD 1 0002007919-25-000056
0002007919-25-000056 20240331 Research And Development Expense 63851000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20231231 Stockholders Equity 5000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0002007919-25-000056 20240331 Weighted Average Number Of Diluted Shares Outstanding 13639000.0000 shares 1 us-gaap/2024
0002007919-25-000056 20250331 Weighted Average Number Of Diluted Shares Outstanding 15468000.0000 shares 1 us-gaap/2024
0002007919-25-000051 20231231 Accounts Receivable Net Current 778000.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Nonrelated Party;
0002007919-25-000051 20241231 Accounts Receivable Net Current 200000.0000 USD 0 us-gaap/2024 Major Customers= Regeneron Pharmaceuticals Inc.; Type Of Arrangement= License Agreement Initial Programs Authorized Program Three;
0002007919-25-000051 20231231 Accrued Liabilities Current 43295000.0000 USD 0 us-gaap/2024
0002007919-25-000051 20241231 Additional Paid In Capital 239715000.0000 USD 0 us-gaap/2024
0002007919-25-000051 20241231 Amortization Of Financing Costs And Discounts 2065000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20231231 Capital Expenditures Incurred But Not Yet Paid 519000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20231231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 277924000.0000 USD 0 us-gaap/2024
0002007919-25-000051 20231231 Earnings Per Share Diluted -20.4800 USD 4 us-gaap/2024
0002007919-25-000051 20241231 Increase Decrease In Accounts Payable 17903000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20231231 Interest Expense Nonoperating 31840000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20241231 Interest Income Nonoperating 10940000.0000 USD 4 0002007919-25-000051
0002007919-25-000051 20231231 Net Cash Provided By Used In Operating Activities -193309000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20231231 Net Income Loss -241361000.0000 USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0002007919-25-000051 20231231 Noncash Operating Lease Expense 1765000.0000 USD 4 0002007919-25-000051
0002007919-25-000051 20231231 Nonmonetary Transaction Gain Loss Recognized On Transfer Net 0.0000 USD 4 0002007919-25-000051
0002007919-25-000051 20241231 Nonmonetary Transaction Gain Loss Recognized On Transfer Net 1998809000.0000 USD 4 0002007919-25-000051
0002007919-25-000051 20231231 Operating Lease Liability Current 2063000.0000 USD 0 us-gaap/2024
0002007919-25-000051 20241231 Operating Lease Liability Current 1595000.0000 USD 0 us-gaap/2024
0002007919-25-000051 20231231 Other Nonoperating Income Expense -580000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20241231 Other Nonoperating Income Expense 75000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20241231 Proceeds From Stock Options Exercised 71678000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20241231 Property Plant And Equipment Net 6200000.0000 USD 0 us-gaap/2024
0002007919-25-000051 20231231 Remeasurement Of Operating Lease Liability And Right Of Use Asset In Connection With2024 Lease Agreement 0.0000 USD 4 0002007919-25-000051
0002007919-25-000051 20231231 Revenues 166000.0000 USD 4 us-gaap/2024 Major Customers= Other Customers; Product Or Service= License Non Affiliate;
0002007919-25-000051 20241231 Revenues 0.0000 USD 4 us-gaap/2024 Major Customers= Other Customers; Product Or Service= License Non Affiliate;
0002007919-25-000051 20231231 Share Based Compensation 24846000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20241231 Stockholders Equity Note Spinoff Transaction -563754000.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0002007919-25-000051 20241231 Stockholders Equity Note Spinoff Transaction -1179970000.0000 USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0002007919-25-000051 20231231 Stock Issued During Period Shares Stock Options Exercised 184000.0000 shares 4 us-gaap/2024 Equity Components= Common Stock;
0002007919-25-000051 20241231 Stock Issued During Period Shares Stock Options Exercised 0.0000 shares 4 us-gaap/2024 Plan Name= Plan2024;
0002007919-25-000051 20231231 Stock Issued During Period Value Stock Options Exercised 2316000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20231231 Stock Issued During Period Value Stock Options Exercised 2316000.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0002007919-25-000056 20240331 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 6397000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20240331 Amortization Of Financing Costs And Discounts 1242000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20250331 Amortization Of Financing Costs And Discounts 533000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20241231 Assets 180767000.0000 USD 0 us-gaap/2024
0002007919-25-000056 20241231 Common Stock Shares Authorized 120000000.0000 shares 0 us-gaap/2024
0002007919-25-000056 20250331 Increase Decrease In Accounts Receivable -183000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20250331 Increase Decrease In Due From Related Parties -23000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20250331 Increase Decrease In Operating Lease Liability -171000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20240331 Increase Decrease In Prepaid Deferred Expense And Other Assets 2361000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20240331 Net Cash Provided By Used In Investing Activities -1119000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20250331 Net Cash Provided By Used In Investing Activities -21000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20250331 Operating Lease Liability Noncurrent 5904000.0000 USD 0 us-gaap/2024
0002007919-25-000056 20250331 Payments Of Debt Issuance Costs Secured Debt 125000.0000 USD 1 0002007919-25-000056
0002007919-25-000056 20241231 Preferred Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024
0002007919-25-000056 20241231 Preferred Stock Shares Authorized 15000000.0000 shares 0 us-gaap/2024
0002007919-25-000056 20250331 Property Plant And Equipment Net 5546000.0000 USD 0 us-gaap/2024
0002007919-25-000056 20250331 Stockholders Equity 243885000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0002007919-25-000051 20241231 Accounts Payable Current 9245000.0000 USD 0 us-gaap/2024
0002007919-25-000051 20241231 Accounts Receivable Net Current 200000.0000 USD 0 us-gaap/2024 Related Party Transaction= Services Performed Under Transition Services Agreement; Related Party Transactions By Related Party= Related Party;
0002007919-25-000051 20231231 Assets 307893000.0000 USD 0 us-gaap/2024
0002007919-25-000051 20231231 Common Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024
0002007919-25-000051 20241231 Common Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024
0002007919-25-000051 20231231 Common Stock Shares Issued 47369511.0000 shares 0 us-gaap/2024
0002007919-25-000051 20231231 Common Stock Shares Outstanding 47369511.0000 shares 0 us-gaap/2024
0002007919-25-000051 20241231 Common Stock Value 1000.0000 USD 0 us-gaap/2024
0002007919-25-000051 20231231 Depreciation Depletion And Amortization 1191000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20241231 Depreciation Depletion And Amortization 2285000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20231231 Increase Decrease In Due From Related Parties -14000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20231231 Interest Paid Net 26717000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20241231 Long Term Debt Noncurrent 0.0000 USD 0 us-gaap/2024
0002007919-25-000051 20231231 Operating Lease Right Of Use Asset 2952000.0000 USD 0 us-gaap/2024
0002007919-25-000051 20231231 Payments Of Private Placement Costs 355000.0000 USD 4 0002007919-25-000051
0002007919-25-000051 20241231 Payments Of Private Placement Costs 0.0000 USD 4 0002007919-25-000051
0002007919-25-000051 20231231 Payments To Acquire Property Plant And Equipment 4593000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20240531 Preferred Stock Shares Authorized 15000000.0000 shares 0 us-gaap/2024
0002007919-25-000051 20231231 Proceeds From Issuance Of Private Placement 200000000.0000 USD 4 us-gaap/2024
0002007919-25-000051 20231231 Revenues 1800000.0000 USD 4 us-gaap/2024 Business Segments= Reportable Segment;
0002007919-25-000051 20221231 Stockholders Equity -372373000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0002007919-25-000056 20241231 Accounts Payable Current 9245000.0000 USD 0 us-gaap/2024
0002007919-25-000056 20241231 Accounts Receivable Net Current 23000.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Related Party;
0002007919-25-000056 20250331 Additional Paid In Capital 243885000.0000 USD 0 us-gaap/2024
0002007919-25-000056 20241231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 152596000.0000 USD 0 us-gaap/2024
0002007919-25-000056 20250331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect 63924000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20240531 Common Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024
0002007919-25-000056 20241231 Common Stock Shares Issued 14475904.0000 shares 0 us-gaap/2024
0002007919-25-000056 20231231 Common Stock Shares Outstanding 47369000.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0002007919-25-000056 20250331 Income Taxes Paid Net 0.0000 USD 1 us-gaap/2024
0002007919-25-000056 20250331 Increase Decrease In Prepaid Deferred Expense And Other Assets -730000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20241231 Liabilities And Stockholders Equity 180767000.0000 USD 0 us-gaap/2024
0002007919-25-000056 20250331 Net Income Loss -43311000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20240531 Preferred Stock Shares Authorized 15000000.0000 shares 0 us-gaap/2024
0002007919-25-000056 20241231 Prepaid Expense And Other Assets Current 7382000.0000 USD 0 us-gaap/2024
0002007919-25-000056 20250331 Research And Development Expense 36877000.0000 USD 1 us-gaap/2024
0002007919-25-000056 20231231 Stockholders Equity 43503000.0000 USD 0 us-gaap/2024
0002007919-25-000056 20241231 Stockholders Equity -106132000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0002007919-25-000056 20250331 Stockholders Equity 1000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0002007919-25-000056 20240331 Warrants Issued 0.0000 USD 1 0002007919-25-000056
0002007919-25-000056 20250331 Warrants Issued 1720000.0000 USD 1 0002007919-25-000056

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
tag The unique identifier (name) for a tag in a specific taxonomy release.
version For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined.
ddate The end date for the data value, rounded to the nearest month end.
qtrs The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value.
uom The unit of measure for the value.
segments Tags used to represent axis and member reporting.
coreg If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity.
value The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point.
footnote The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank.

Tags

tag version custom abstract datatype iord crdr tlabel doc
Increase Decrease In Accounts Receivable us-gaap/2024 0 0 monetary D C Increase (Decrease) in Accounts Receivable The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
Stock Issued During Period Value Stock Options Exercised us-gaap/2024 0 0 monetary D C Stock Issued During Period, Value, Stock Options Exercised Value of stock issued as a result of the exercise of stock options.
Assets Current us-gaap/2024 0 0 monetary I D Assets, Current Amount of asset recognized for present right to economic benefit, classified as current.
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 0 0 monetary I D Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Increase Decrease In Other Noncurrent Assets us-gaap/2024 0 0 monetary D C Increase (Decrease) in Other Noncurrent Assets Amount of increase (decrease) in noncurrent assets classified as other.
Operating Lease Liability Current us-gaap/2024 0 0 monetary I C Operating Lease, Liability, Current Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.
Receivable For Proceeds From The Exercise Of Stock Options 0002007919-25-000056 1 0 monetary D D Receivable For Proceeds From The Exercise Of Stock Options Receivable For Proceeds From The Exercise Of Stock Options
Adjustments To Additional Paid In Capital Warrant Issued us-gaap/2024 0 0 monetary D C Adjustments to Additional Paid in Capital, Warrant Issued Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.
Payments To Acquire Property Plant And Equipment us-gaap/2024 0 0 monetary D C Payments to Acquire Property, Plant, and Equipment The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
Nonmonetary Transaction Gain Loss Recognized On Transfer Net 0002007919-25-000051 1 0 monetary D C Nonmonetary Transaction, Gain (Loss) Recognized On Transfer, Net Nonmonetary Transaction, Gain (Loss) Recognized On Transfer, Net
Stockholder Equity Spinoff Transaction Decrease In Common Stock 0002007919-25-000051 1 0 shares D Stockholder Equity, Spinoff Transaction, Decrease In Common Stock Stockholder Equity, Spinoff Transaction, Decrease In Common Stock
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest us-gaap/2024 0 0 monetary D C Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
Increase Decrease In Contract With Customer Liability us-gaap/2024 0 0 monetary D D Increase (Decrease) in Contract with Customer, Liability Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.
Liabilities us-gaap/2024 0 0 monetary I C Liabilities Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.
Liabilities And Stockholders Equity us-gaap/2024 0 0 monetary I C Liabilities and Equity Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
Proceeds From Issuance Of Private Placement us-gaap/2024 0 0 monetary D D Proceeds from Issuance of Private Placement The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.
Proceeds From Stock Options Exercised us-gaap/2024 0 0 monetary D D Proceeds from Stock Options Exercised Amount of cash inflow from exercise of option under share-based payment arrangement.
Retained Earnings Accumulated Deficit us-gaap/2024 0 0 monetary I C Retained Earnings (Accumulated Deficit) Amount of accumulated undistributed earnings (deficit).
Depreciation Depletion And Amortization us-gaap/2024 0 0 monetary D D Depreciation, Depletion and Amortization The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
Interest Income Nonoperating 0002007919-25-000056 1 0 monetary D C Interest Income, Nonoperating Interest Income, Nonoperating
Accounts Receivable Net Current us-gaap/2024 0 0 monetary I D Accounts Receivable, after Allowance for Credit Loss, Current Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Additional Paid In Capital us-gaap/2024 0 0 monetary I C Additional Paid in Capital Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.
Common Stock Par Or Stated Value Per Share us-gaap/2024 0 0 perShare I Common Stock, Par or Stated Value Per Share Face amount or stated value per share of common stock.
Common Stock Shares Outstanding us-gaap/2024 0 0 shares I Common Stock, Shares, Outstanding Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
Income Tax Expense Benefit us-gaap/2024 0 0 monetary D D Income Tax Expense (Benefit) Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Net Income Loss us-gaap/2024 0 0 monetary D C Net Income (Loss) Attributable to Parent The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Other Noncash Income us-gaap/2024 0 0 monetary D C Other Noncash Income Amount of income or gain included in net income that result in no cash inflow (outflow), classified as other.
Stockholders Equity us-gaap/2024 0 0 monetary I C Equity, Attributable to Parent Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
Weighted Average Number Of Diluted Shares Outstanding us-gaap/2024 0 0 shares D Weighted Average Number of Shares Outstanding, Diluted The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Remeasurement Of Operating Lease Liability And Right Of Use Asset In Connection With2024 Lease Agreement 0002007919-25-000051 1 0 monetary D C Remeasurement Of Operating Lease Liability And Right-Of-Use Asset In Connection With 2024 Lease Agreement Remeasurement Of Operating Lease Liability And Right-Of-Use Asset In Connection With 2024 Lease Agreement
Assets us-gaap/2024 0 0 monetary I D Assets Amount of asset recognized for present right to economic benefit.
Common Stock Shares Issued us-gaap/2024 0 0 shares I Common Stock, Shares, Issued Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
Earnings Per Share Diluted us-gaap/2024 0 0 perShare D Earnings Per Share, Diluted The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
Operating Lease Right Of Use Asset us-gaap/2024 0 0 monetary I D Operating Lease, Right-of-Use Asset Amount of lessee's right to use underlying asset under operating lease.
Other Assets Noncurrent us-gaap/2024 0 0 monetary I D Other Assets, Noncurrent Amount of noncurrent assets classified as other.
Stock Issued During Period Shares Conversion Of Convertible Securities us-gaap/2024 0 0 shares D Stock Issued During Period, Shares, Conversion of Convertible Securities Number of shares issued during the period as a result of the conversion of convertible securities.
Interest Income Nonoperating 0002007919-25-000051 1 0 monetary D C Interest Income, Nonoperating Interest Income, Nonoperating
Warrants Issued 0002007919-25-000056 1 0 monetary D C Warrants Issued Warrants Issued
Accrued Liabilities Current us-gaap/2024 0 0 monetary I C Accrued Liabilities, Current Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Interest Expense Nonoperating us-gaap/2024 0 0 monetary D D Interest Expense, Nonoperating Amount of interest expense classified as nonoperating.
Liabilities Current us-gaap/2024 0 0 monetary I C Liabilities, Current Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
Preferred Stock Shares Issued us-gaap/2024 0 0 shares I Preferred Stock, Shares Issued Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.
Share Based Compensation us-gaap/2024 0 0 monetary D D Share-Based Payment Arrangement, Noncash Expense Amount of noncash expense for share-based payment arrangement.
Amortization Of Financing Costs And Discounts us-gaap/2024 0 0 monetary D D Amortization of Debt Issuance Costs and Discounts Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.
Cash And Cash Equivalents At Carrying Value us-gaap/2024 0 0 monetary I D Cash and Cash Equivalents, at Carrying Value Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
Income Taxes Paid Net us-gaap/2024 0 0 monetary D C Income Taxes Paid, Net Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.
Increase Decrease In Prepaid Deferred Expense And Other Assets us-gaap/2024 0 0 monetary D C Increase (Decrease) in Prepaid Expense and Other Assets Amount of increase (decrease) in prepaid expenses, and assets classified as other.
Nonmonetary Transaction Gain Loss Recognized On Transfer us-gaap/2024 0 0 monetary D C Nonmonetary Transaction, Gain (Loss) Recognized on Transfer Disclosure of the difference in values (gain (loss)) between the nonmonetary assets or liabilities exchanged with another entity inclusive of boot (small monetary consideration).
Nonoperating Income Expense us-gaap/2024 0 0 monetary D C Nonoperating Income (Expense) The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Preferred Stock Value us-gaap/2024 0 0 monetary I C Preferred Stock, Value, Issued Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
Issuance Of Common Stock And Pre Funded Warrants In Private Placement Net Of Issuance Costs In Common Stock 0002007919-25-000051 1 0 shares D Issuance Of Common Stock And Pre-Funded Warrants In Private Placement, Net Of Issuance Costs, In Common Stock Issuance Of Common Stock And Pre-Funded Warrants In Private Placement, Net Of Issuance Costs, In Common Stock
Stock And Pre Funded Warrants Issued During Period Value 0002007919-25-000051 1 0 monetary D C Stock And Pre-Funded Warrants Issued During Period, Value Stock And Pre-Funded Warrants Issued During Period, Value
Net Cash Provided By Used In Operating Activities us-gaap/2024 0 0 monetary D Net Cash Provided by (Used in) Operating Activities Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
Operating Expenses us-gaap/2024 0 0 monetary D D Operating Expenses Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
Operating Income Loss us-gaap/2024 0 0 monetary D C Operating Income (Loss) The net result for the period of deducting operating expenses from operating revenues.
Prepaid Expense And Other Assets Current us-gaap/2024 0 0 monetary I D Prepaid Expense and Other Assets, Current Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
Noncash Operating Lease Expense 0002007919-25-000051 1 0 monetary D D Noncash Operating Lease Expense Noncash Operating Lease Expense
Research And Development Expense us-gaap/2024 0 0 monetary D D Research and Development Expense Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.
Capital Expenditures Incurred But Not Yet Paid us-gaap/2024 0 0 monetary D C Capital Expenditures Incurred but Not yet Paid Future cash outflow to pay for purchases of fixed assets that have occurred.
Common Stock Value us-gaap/2024 0 0 monetary I C Common Stock, Value, Issued Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
General And Administrative Expense us-gaap/2024 0 0 monetary D D General and Administrative Expense The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
Income Loss From Equity Method Investments us-gaap/2024 0 0 monetary D C Income (Loss) from Equity Method Investments Amount of income (loss) for proportionate share of equity method investee's income (loss).
Revenues us-gaap/2024 0 0 monetary D C Revenues Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
Stock Issued During Period Shares New Issues us-gaap/2024 0 0 shares D Stock Issued During Period, Shares, New Issues Number of new stock issued during the period.
Payments Of Private Placement Costs 0002007919-25-000051 1 0 monetary D C Payments of Private Placement Costs Payments of Stock Issuance and Warrants Costs
Accounts Payable Current us-gaap/2024 0 0 monetary I C Accounts Payable, Current Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect us-gaap/2024 0 0 monetary D D Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Commitments And Contingencies us-gaap/2024 0 0 monetary I C Commitments and Contingencies Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
Common Stock Shares Authorized us-gaap/2024 0 0 shares I Common Stock, Shares Authorized The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
Gain Loss On Sale Of Property Plant Equipment us-gaap/2024 0 0 monetary D C Gain (Loss) on Disposition of Property Plant Equipment Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.
Increase Decrease In Accounts Payable us-gaap/2024 0 0 monetary D D Increase (Decrease) in Accounts Payable The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
Increase Decrease In Operating Lease Liability us-gaap/2024 0 0 monetary D D Increase (Decrease) in Operating Lease Liability Amount of increase (decrease) in obligation for operating lease.
Increase Decrease In Other Receivables us-gaap/2024 0 0 monetary D C Increase (Decrease) in Other Receivables Amount of increase (decrease) in receivables classified as other.
Interest Paid Net us-gaap/2024 0 0 monetary D C Interest Paid, Excluding Capitalized Interest, Operating Activities Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.
Net Cash Provided By Used In Financing Activities us-gaap/2024 0 0 monetary D D Net Cash Provided by (Used in) Financing Activities Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Preferred Stock Par Or Stated Value Per Share us-gaap/2024 0 0 perShare I Preferred Stock, Par or Stated Value Per Share Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
Stockholders Equity Note Spinoff Transaction us-gaap/2024 0 0 monetary D C Stockholders' Equity Note, Spinoff Transaction The change in equity as a result of a spin-off transaction (a regular or reverse spin-off) which is based on the recorded amounts.
Payments Of Debt Issuance Costs Secured Debt 0002007919-25-000056 1 0 monetary D C Payments of Debt Issuance Costs, Secured Debt Payments of Debt Issuance Costs, Secured Debt
Net Cash Provided By Used In Investing Activities us-gaap/2024 0 0 monetary D D Net Cash Provided by (Used in) Investing Activities Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value us-gaap/2024 0 0 monetary D C APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.
Earnings Per Share Basic us-gaap/2024 0 0 perShare D Earnings Per Share, Basic The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments us-gaap/2024 0 0 monetary D C Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.
Increase Decrease In Due From Related Parties us-gaap/2024 0 0 monetary D C Increase (Decrease) in Due from Related Parties The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.
Stock Issued During Period Shares Stock Options Exercised us-gaap/2024 0 0 shares D Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Number of share options (or share units) exercised during the current period.
Other Nonoperating Income Expense us-gaap/2024 0 0 monetary D C Other Nonoperating Income (Expense) Amount of income (expense) related to nonoperating activities, classified as other.
Preferred Stock Shares Authorized us-gaap/2024 0 0 shares I Preferred Stock, Shares Authorized The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
Preferred Stock Shares Outstanding us-gaap/2024 0 0 shares I Preferred Stock, Shares Outstanding Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
Proceeds From Issuance Of Secured Debt us-gaap/2024 0 0 monetary D D Proceeds from Issuance of Secured Debt The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.
Stock Issued During Period Value New Issues us-gaap/2024 0 0 monetary D C Stock Issued During Period, Value, New Issues Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
Increase Decrease In Accrued Liabilities us-gaap/2024 0 0 monetary D D Increase (Decrease) in Accrued Liabilities The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.
Long Term Debt Noncurrent us-gaap/2024 0 0 monetary I C Long-Term Debt, Excluding Current Maturities Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.
Operating Lease Liability Noncurrent us-gaap/2024 0 0 monetary I C Operating Lease, Liability, Noncurrent Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
Property Plant And Equipment Net us-gaap/2024 0 0 monetary I D Property, Plant and Equipment, Net Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
Weighted Average Number Of Shares Outstanding Basic us-gaap/2024 0 0 shares D Weighted Average Number of Shares Outstanding, Basic Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
Noncash Operating Lease Expense 0002007919-25-000056 1 0 monetary D D Noncash Operating Lease Expense Noncash Operating Lease Expense

Description
Field Name Field Description
tag The unique identifier (name) for a tag in a specific taxonomy release.
version For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined.
custom 1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns.
abstract 1 if the tag is not used to represent a numeric fact.
datatype If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag.
iord If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration.
crdr If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL.
tlabel If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here.
doc The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL.

Presentation of Statements

adsh report line stmt inpth rfile tag version plabel negating
0002007919-25-000051 2 11 BS 0 H Prepaid Expense And Other Assets Current us-gaap/2024 Prepaid expenses and other current assets 0
0002007919-25-000051 6 19 CF 0 H Increase Decrease In Operating Lease Liability us-gaap/2024 Operating lease liability 0
0002007919-25-000051 6 20 CF 0 H Increase Decrease In Contract With Customer Liability us-gaap/2024 Deferred revenue, current portion 0
0002007919-25-000051 6 21 CF 0 H Net Cash Provided By Used In Operating Activities us-gaap/2024 Net cash used in operating activities 0
0002007919-25-000051 6 23 CF 0 H Payments To Acquire Property Plant And Equipment us-gaap/2024 Purchase of fixed assets 1
0002007919-25-000051 6 24 CF 0 H Net Cash Provided By Used In Investing Activities us-gaap/2024 Net cash used in investing activities 0
0002007919-25-000051 6 26 CF 0 H Proceeds From Issuance Of Private Placement us-gaap/2024 Proceeds from issuance of common stock and pre-funded warrants in private placement 0
0002007919-25-000051 6 27 CF 0 H Payments Of Private Placement Costs 0002007919-25-000051 Issuance costs associated with issuance of common stock and pre-funded warrants in private placement 1
0002007919-25-000051 6 28 CF 0 H Proceeds From Stock Options Exercised us-gaap/2024 Proceeds from exercise of stock options 0
0002007919-25-000051 6 29 CF 0 H Net Cash Provided By Used In Financing Activities us-gaap/2024 Net cash provided by financing activities 0
0002007919-25-000051 6 30 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect us-gaap/2024 Net increase (decrease) in cash 0
0002007919-25-000051 6 31 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 Cash and cash equivalents at beginning of period 0
0002007919-25-000051 6 32 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 Cash and cash equivalents at end of period 0
0002007919-25-000051 6 34 CF 0 H Interest Paid Net us-gaap/2024 Cash paid for interest 0
0002007919-25-000051 6 35 CF 0 H Income Taxes Paid Net us-gaap/2024 Cash paid for income taxes 0
0002007919-25-000051 6 37 CF 0 H Remeasurement Of Operating Lease Liability And Right Of Use Asset In Connection With2024 Lease Agreement 0002007919-25-000051 Remeasurement of operating lease liability and right-of-use asset in connection with 2024 Lease Agreement 0
0002007919-25-000051 6 38 CF 0 H Capital Expenditures Incurred But Not Yet Paid us-gaap/2024 Payable for purchase of fixed assets 0
0002007919-25-000056 2 9 BS 0 H Cash And Cash Equivalents At Carrying Value us-gaap/2024 Cash and cash equivalents 0
0002007919-25-000056 2 10 BS 0 H Accounts Receivable Net Current us-gaap/2024 Accounts receivable 0
0002007919-25-000056 2 11 BS 0 H Prepaid Expense And Other Assets Current us-gaap/2024 Prepaid expenses and other current assets 0
0002007919-25-000056 2 12 BS 0 H Assets Current us-gaap/2024 Total current assets 0
0002007919-25-000056 2 13 BS 0 H Property Plant And Equipment Net us-gaap/2024 Property and equipment, net 0
0002007919-25-000056 2 14 BS 0 H Operating Lease Right Of Use Asset us-gaap/2024 Operating right-of-use asset 0
0002007919-25-000056 2 15 BS 0 H Other Assets Noncurrent us-gaap/2024 Other non-current assets 0
0002007919-25-000056 2 16 BS 0 H Assets us-gaap/2024 Total assets 0
0002007919-25-000056 2 19 BS 0 H Accounts Payable Current us-gaap/2024 Accounts payable 0
0002007919-25-000056 2 20 BS 0 H Accrued Liabilities Current us-gaap/2024 Accrued expenses 0
0002007919-25-000056 2 21 BS 0 H Operating Lease Liability Current us-gaap/2024 Current portion of operating lease liability 0
0002007919-25-000056 2 22 BS 0 H Liabilities Current us-gaap/2024 Total current liabilities 0
0002007919-25-000056 2 23 BS 0 H Long Term Debt Noncurrent us-gaap/2024 Long-term debt, net 0
0002007919-25-000056 2 24 BS 0 H Operating Lease Liability Noncurrent us-gaap/2024 Non-current portion of operating lease liability 0
0002007919-25-000056 2 25 BS 0 H Liabilities us-gaap/2024 Total liabilities 0
0002007919-25-000056 2 28 BS 0 H Preferred Stock Value us-gaap/2024 Preferred stock, $0.0001 par value; 15,000,000 shares authorized as of March 31, 2025 and December 31, 2024; no shares issued or outstanding as of March 31, 2025 and December 31, 2024. 0
0002007919-25-000056 2 29 BS 0 H Common Stock Value us-gaap/2024 Common stock, $0.0001 par value; 120,000,000 shares authorized as of March 31, 2025 and December 31, 2024; 14,475,904 shares issued and outstanding as of March 31, 2025 and December 31, 2024. 0
0002007919-25-000056 2 30 BS 0 H Additional Paid In Capital us-gaap/2024 Additional paid-in-capital 0
0002007919-25-000056 2 31 BS 0 H Retained Earnings Accumulated Deficit us-gaap/2024 Accumulated deficit 0
0002007919-25-000056 2 32 BS 0 H Stockholders Equity us-gaap/2024 Total stockholders equity 0
0002007919-25-000056 2 33 BS 0 H Liabilities And Stockholders Equity us-gaap/2024 Total liabilities and stockholders equity 0
0002007919-25-000056 3 1 BS 1 H Preferred Stock Par Or Stated Value Per Share us-gaap/2024 Preferred stock, par value (in dollars per share) 0
0002007919-25-000056 3 2 BS 1 H Preferred Stock Shares Authorized us-gaap/2024 Preferred stock, shares authorized (in shares) 0
0002007919-25-000056 3 3 BS 1 H Preferred Stock Shares Issued us-gaap/2024 Preferred stock, shares issued (in shares) 0
0002007919-25-000056 3 4 BS 1 H Preferred Stock Shares Outstanding us-gaap/2024 Preferred stock, shares outstanding (in shares) 0
0002007919-25-000056 3 5 BS 1 H Common Stock Par Or Stated Value Per Share us-gaap/2024 Common stock, par value (in dollars per share) 0
0002007919-25-000056 3 6 BS 1 H Common Stock Shares Authorized us-gaap/2024 Common stock, shares authorized (in shares) 0
0002007919-25-000056 3 7 BS 1 H Common Stock Shares Issued us-gaap/2024 Common stock, shares issued (in shares) 0
0002007919-25-000056 3 8 BS 1 H Common Stock Shares Outstanding us-gaap/2024 Common stock, shares outstanding (in shares) 0
0002007919-25-000056 4 2 IS 0 H Research And Development Expense us-gaap/2024 Research and development 0
0002007919-25-000056 4 3 IS 0 H General And Administrative Expense us-gaap/2024 General and administrative 0
0002007919-25-000056 4 4 IS 0 H Operating Expenses us-gaap/2024 Total operating expenses 0
0002007919-25-000056 4 5 IS 0 H Operating Income Loss us-gaap/2024 Loss from operations 0
0002007919-25-000056 4 7 IS 0 H Interest Expense Nonoperating us-gaap/2024 Interest expense 1
0002007919-25-000056 4 8 IS 0 H Interest Income Nonoperating 0002007919-25-000056 Interest income 0
0002007919-25-000056 4 9 IS 0 H Other Nonoperating Income Expense us-gaap/2024 Other income (expense), net 0
0002007919-25-000056 4 10 IS 0 H Nonoperating Income Expense us-gaap/2024 Total other expense 0
0002007919-25-000056 4 11 IS 0 H Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest us-gaap/2024 Loss before income tax expense 0
0002007919-25-000056 4 12 IS 0 H Income Tax Expense Benefit us-gaap/2024 Provision for income taxes 0
0002007919-25-000056 4 13 IS 0 H Net Income Loss us-gaap/2024 Net loss 0
0002007919-25-000056 4 15 IS 0 H Earnings Per Share Basic us-gaap/2024 Basic (in dollars per share) 0
0002007919-25-000056 4 16 IS 0 H Earnings Per Share Diluted us-gaap/2024 Diluted (in dollars per share) 0
0002007919-25-000056 4 18 IS 0 H Weighted Average Number Of Shares Outstanding Basic us-gaap/2024 Basic (in shares) 0
0002007919-25-000056 4 19 IS 0 H Weighted Average Number Of Diluted Shares Outstanding us-gaap/2024 Diluted (in shares) 0
0002007919-25-000056 5 9 EQ 0 H Common Stock Shares Outstanding us-gaap/2024 Beginning balance (in shares) 0
0002007919-25-000056 5 10 EQ 0 H Stockholders Equity us-gaap/2024 Beginning balance 0
0002007919-25-000056 5 11 EQ 0 H Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value us-gaap/2024 Stock-based compensation expense 0
0002007919-25-000056 5 12 EQ 0 H Adjustments To Additional Paid In Capital Warrant Issued us-gaap/2024 Issuance of warrants in connection with 2025 Loan Agreement 0
0002007919-25-000056 5 13 EQ 0 H Stock Issued During Period Shares Stock Options Exercised us-gaap/2024 Issuance of shares upon exercise of stock options (in shares) 0
0002007919-25-000056 5 14 EQ 0 H Stock Issued During Period Value Stock Options Exercised us-gaap/2024 Issuance of shares upon exercise of stock options 0
0002007919-25-000056 5 15 EQ 0 H Net Income Loss us-gaap/2024 Net loss 0
0002007919-25-000056 5 16 EQ 0 H Common Stock Shares Outstanding us-gaap/2024 Ending balance (in shares) 0
0002007919-25-000056 5 17 EQ 0 H Stockholders Equity us-gaap/2024 Ending balance 0
0002007919-25-000056 6 2 CF 0 H Net Income Loss us-gaap/2024 Net loss 0
0002007919-25-000056 6 4 CF 0 H Depreciation Depletion And Amortization us-gaap/2024 Depreciation and amortization 0
0002007919-25-000056 6 5 CF 0 H Amortization Of Financing Costs And Discounts us-gaap/2024 Accretion of debt discount and non-cash interest expense 0
0002007919-25-000056 6 6 CF 0 H Share Based Compensation us-gaap/2024 Stock-based compensation expense 0
0002007919-25-000056 6 7 CF 0 H Noncash Operating Lease Expense 0002007919-25-000056 Non-cash lease expense 0
0002007919-25-000056 6 9 CF 0 H Increase Decrease In Accounts Receivable us-gaap/2024 Accounts receivable 1
0002007919-25-000056 6 10 CF 0 H Increase Decrease In Other Receivables us-gaap/2024 Other receivables 0
0002007919-25-000056 6 11 CF 0 H Increase Decrease In Due From Related Parties us-gaap/2024 Receivables from related parties 1
0002007919-25-000056 6 12 CF 0 H Increase Decrease In Prepaid Deferred Expense And Other Assets us-gaap/2024 Prepaid expenses and other current assets 1
0002007919-25-000056 6 13 CF 0 H Increase Decrease In Other Noncurrent Assets us-gaap/2024 Other non-current assets 1
0002007919-25-000056 6 14 CF 0 H Increase Decrease In Accounts Payable us-gaap/2024 Accounts payable 0
0002007919-25-000056 6 15 CF 0 H Increase Decrease In Accrued Liabilities us-gaap/2024 Accrued expenses 0
0002007919-25-000056 6 16 CF 0 H Increase Decrease In Operating Lease Liability us-gaap/2024 Operating lease liability 0
0002007919-25-000056 6 17 CF 0 H Net Cash Provided By Used In Operating Activities us-gaap/2024 Net cash used in operating activities 0
0002007919-25-000056 6 19 CF 0 H Payments To Acquire Property Plant And Equipment us-gaap/2024 Purchase of fixed assets 1
0002007919-25-000056 6 20 CF 0 H Net Cash Provided By Used In Investing Activities us-gaap/2024 Net cash used in investing activities 0
0002007919-25-000056 6 22 CF 0 H Proceeds From Issuance Of Secured Debt us-gaap/2024 Proceeds from the issuance of debt 0
0002007919-25-000056 6 23 CF 0 H Payments Of Debt Issuance Costs Secured Debt 0002007919-25-000056 Payment of fees associated with debt 1
0002007919-25-000056 6 24 CF 0 H Proceeds From Stock Options Exercised us-gaap/2024 Proceeds from the exercise of stock options 0
0002007919-25-000056 6 25 CF 0 H Net Cash Provided By Used In Financing Activities us-gaap/2024 Net cash provided by financing activities 0
0002007919-25-000056 6 26 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect us-gaap/2024 Net increase (decrease) in cash and cash equivalents 0
0002007919-25-000056 6 27 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 Cash and cash equivalents at beginning of period 0
0002007919-25-000056 6 28 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 Cash and cash equivalents at end of period 0
0002007919-25-000056 6 30 CF 0 H Interest Paid Net us-gaap/2024 Cash paid for interest 0
0002007919-25-000056 6 31 CF 0 H Income Taxes Paid Net us-gaap/2024 Cash paid for income taxes 0
0002007919-25-000056 6 33 CF 0 H Warrants Issued 0002007919-25-000056 Fair value of warrants issued to lender in conjunction with 2025 Loan (as defined in Note 3) 0
0002007919-25-000056 6 34 CF 0 H Capital Expenditures Incurred But Not Yet Paid us-gaap/2024 Payable for purchase of fixed assets 0
0002007919-25-000056 6 35 CF 0 H Receivable For Proceeds From The Exercise Of Stock Options 0002007919-25-000056 Receivable for proceeds from the exercise of stock options 0
0002007919-25-000051 2 9 BS 0 H Cash And Cash Equivalents At Carrying Value us-gaap/2024 Cash and cash equivalents 0
0002007919-25-000051 2 10 BS 0 H Accounts Receivable Net Current us-gaap/2024 Accounts receivable 0
0002007919-25-000051 2 12 BS 0 H Assets Current us-gaap/2024 Total current assets 0
0002007919-25-000051 2 13 BS 0 H Property Plant And Equipment Net us-gaap/2024 Property and equipment, net 0
0002007919-25-000051 2 14 BS 0 H Operating Lease Right Of Use Asset us-gaap/2024 Operating right-of-use asset 0
0002007919-25-000051 2 15 BS 0 H Other Assets Noncurrent us-gaap/2024 Other non-current assets 0
0002007919-25-000051 2 16 BS 0 H Assets us-gaap/2024 Total assets 0
0002007919-25-000051 2 19 BS 0 H Accounts Payable Current us-gaap/2024 Accounts payable 0
0002007919-25-000051 2 20 BS 0 H Accrued Liabilities Current us-gaap/2024 Accrued expenses 0
0002007919-25-000051 2 21 BS 0 H Operating Lease Liability Current us-gaap/2024 Current portion of operating lease liability 0
0002007919-25-000051 2 22 BS 0 H Liabilities Current us-gaap/2024 Total current liabilities 0
0002007919-25-000051 2 23 BS 0 H Long Term Debt Noncurrent us-gaap/2024 Long-term debt, including final payment fee 0
0002007919-25-000051 2 24 BS 0 H Operating Lease Liability Noncurrent us-gaap/2024 Non-current portion of operating lease liability 0
0002007919-25-000051 2 25 BS 0 H Liabilities us-gaap/2024 Total liabilities 0
0002007919-25-000051 2 26 BS 0 H Commitments And Contingencies us-gaap/2024 Commitments and contingencies (Note 10) 0
0002007919-25-000051 2 28 BS 0 H Preferred Stock Value us-gaap/2024 Preferred stock, $0.0001 par value, 15,000,000 shares authorized and no shares outstanding as of December 31, 2024 and December 31, 2023 0
0002007919-25-000051 2 29 BS 0 H Common Stock Value us-gaap/2024 Common stock, $0.0001 par value, 120,000,000 shares authorized as of December 31, 2024 and December 31, 2023; 14,475,904 and 47,369,511 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively 0
0002007919-25-000051 2 30 BS 0 H Additional Paid In Capital us-gaap/2024 Additional paid-in-capital 0
0002007919-25-000051 2 31 BS 0 H Retained Earnings Accumulated Deficit us-gaap/2024 Accumulated deficit 0
0002007919-25-000051 2 32 BS 0 H Stockholders Equity us-gaap/2024 Total stockholders equity 0
0002007919-25-000051 2 33 BS 0 H Liabilities And Stockholders Equity us-gaap/2024 Total liabilities and stockholders equity 0
0002007919-25-000051 3 1 BS 1 H Preferred Stock Par Or Stated Value Per Share us-gaap/2024 Preferred stock, par value (in dollars per share) 0
0002007919-25-000051 3 2 BS 1 H Preferred Stock Shares Authorized us-gaap/2024 Preferred stock, shares authorized (in shares) 0
0002007919-25-000051 3 3 BS 1 H Preferred Stock Shares Outstanding us-gaap/2024 Preferred stock, shares outstanding (in shares) 0
0002007919-25-000051 3 4 BS 1 H Common Stock Par Or Stated Value Per Share us-gaap/2024 Common stock, par value (in dollars per share) 0
0002007919-25-000051 3 5 BS 1 H Common Stock Shares Authorized us-gaap/2024 Common stock, shares authorized (in shares) 0
0002007919-25-000051 3 6 BS 1 H Common Stock Shares Issued us-gaap/2024 Common stock, shares issued (in shares) 0
0002007919-25-000051 3 7 BS 1 H Common Stock Shares Outstanding us-gaap/2024 Common stock, shares outstanding (in shares) 0
0002007919-25-000051 4 7 IS 0 H Revenues us-gaap/2024 Total revenue 0
0002007919-25-000051 4 9 IS 0 H Research And Development Expense us-gaap/2024 Research and development 0
0002007919-25-000051 4 10 IS 0 H General And Administrative Expense us-gaap/2024 General and administrative 0
0002007919-25-000051 4 11 IS 0 H Operating Expenses us-gaap/2024 Total operating expenses 0
0002007919-25-000051 4 12 IS 0 H Operating Income Loss us-gaap/2024 Loss from operations 0
0002007919-25-000051 4 14 IS 0 H Nonmonetary Transaction Gain Loss Recognized On Transfer us-gaap/2024 Gain related to transaction with Acquirer 0
0002007919-25-000051 4 15 IS 0 H Interest Expense Nonoperating us-gaap/2024 Interest expense 1
0002007919-25-000051 4 16 IS 0 H Interest Income Nonoperating 0002007919-25-000051 Interest income 0
0002007919-25-000051 4 17 IS 0 H Other Nonoperating Income Expense us-gaap/2024 Other income (expense), net 0
0002007919-25-000051 4 18 IS 0 H Nonoperating Income Expense us-gaap/2024 Total other income (expense) 0
0002007919-25-000051 4 19 IS 0 H Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments us-gaap/2024 Income (loss) before provision for income taxes 0
0002007919-25-000051 4 20 IS 0 H Income Tax Expense Benefit us-gaap/2024 Provision for income taxes 0
0002007919-25-000051 4 21 IS 0 H Income Loss From Equity Method Investments us-gaap/2024 Loss on equity method investment 1
0002007919-25-000051 4 22 IS 0 H Net Income Loss us-gaap/2024 Net income (loss) 0
0002007919-25-000051 4 23 IS 0 H Earnings Per Share Basic us-gaap/2024 Net loss per share, basic (in dollars per share) 0
0002007919-25-000051 4 24 IS 0 H Earnings Per Share Diluted us-gaap/2024 Net loss per share, diluted (in dollars per share) 0
0002007919-25-000051 4 25 IS 0 H Weighted Average Number Of Shares Outstanding Basic us-gaap/2024 Weighted-average shares of common stock and pre-funded warrants outstanding, basic (in shares) 0
0002007919-25-000051 4 26 IS 0 H Weighted Average Number Of Diluted Shares Outstanding us-gaap/2024 Weighted-average shares of common stock and pre-funded warrants outstanding, diluted (in shares) 0
0002007919-25-000051 5 9 EQ 0 H Common Stock Shares Outstanding us-gaap/2024 Beginning balance (in shares) 0
0002007919-25-000051 5 10 EQ 0 H Stockholders Equity us-gaap/2024 Beginning balance 0
0002007919-25-000051 5 11 EQ 0 H Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value us-gaap/2024 Stock-based compensation expense 0
0002007919-25-000051 5 12 EQ 0 H Stock Issued During Period Shares Stock Options Exercised us-gaap/2024 Stock options exercised (in shares) 0
0002007919-25-000051 5 13 EQ 0 H Stock Issued During Period Value Stock Options Exercised us-gaap/2024 Issuance of shares upon exercise of stock options 0
0002007919-25-000051 5 14 EQ 0 H Issuance Of Common Stock And Pre Funded Warrants In Private Placement Net Of Issuance Costs In Common Stock 0002007919-25-000051 Issuance of common stock and pre-funded warrants in private placement, net of issuance costs (in shares) 0
0002007919-25-000051 5 15 EQ 0 H Stock And Pre Funded Warrants Issued During Period Value 0002007919-25-000051 Issuance of common stock and pre-funded warrants in private placement, net of issuance costs 0
0002007919-25-000051 5 16 EQ 0 H Stock Issued During Period Shares Conversion Of Convertible Securities us-gaap/2024 Issuance of shares upon exercise of warrants (in shares) 0
0002007919-25-000056 2 26 BS 0 H Commitments And Contingencies us-gaap/2024 Commitments and contingencies (Note 8) 0
0002007919-25-000051 5 17 EQ 0 H Stockholder Equity Spinoff Transaction Decrease In Common Stock 0002007919-25-000051 Acquisition of Former Parents common stock, stock options, and warrants by the Acquirer (in shares) 1
0002007919-25-000051 5 18 EQ 0 H Stockholders Equity Note Spinoff Transaction us-gaap/2024 Acquisition of Former Parents common stock, stock options, and warrants by the Acquirer 0
0002007919-25-000051 5 19 EQ 0 H Stock Issued During Period Shares New Issues us-gaap/2024 Issuance of shares in Distribution (in shares) 0
0002007919-25-000051 5 20 EQ 0 H Stock Issued During Period Value New Issues us-gaap/2024 Issuance of shares in Distribution 0
0002007919-25-000051 5 21 EQ 0 H Net Income Loss us-gaap/2024 Net (loss) income 0
0002007919-25-000051 5 22 EQ 0 H Common Stock Shares Outstanding us-gaap/2024 Ending balance (in shares) 0
0002007919-25-000051 5 23 EQ 0 H Stockholders Equity us-gaap/2024 Ending balance 0
0002007919-25-000051 6 2 CF 0 H Net Income Loss us-gaap/2024 Net income (loss) 0
0002007919-25-000051 6 4 CF 0 H Depreciation Depletion And Amortization us-gaap/2024 Total depreciation and amortization expense 0
0002007919-25-000051 6 5 CF 0 H Amortization Of Financing Costs And Discounts us-gaap/2024 Accretion of debt discount and non-cash interest expense 0
0002007919-25-000051 6 6 CF 0 H Share Based Compensation us-gaap/2024 Stock-based compensation expense 0
0002007919-25-000051 6 7 CF 0 H Noncash Operating Lease Expense 0002007919-25-000051 Non-cash lease expense 0
0002007919-25-000051 6 8 CF 0 H Nonmonetary Transaction Gain Loss Recognized On Transfer Net 0002007919-25-000051 -1998809000 1
0002007919-25-000051 6 9 CF 0 H Income Loss From Equity Method Investments us-gaap/2024 Loss on equity method investment 1
0002007919-25-000051 6 10 CF 0 H Other Noncash Income us-gaap/2024 Non-cash license revenue 1
0002007919-25-000051 6 11 CF 0 H Gain Loss On Sale Of Property Plant Equipment us-gaap/2024 Loss on disposal of fixed assets 1
0002007919-25-000051 6 13 CF 0 H Increase Decrease In Accounts Receivable us-gaap/2024 Accounts receivable 1
0002007919-25-000051 6 14 CF 0 H Increase Decrease In Due From Related Parties us-gaap/2024 Receivables from related parties 1
0002007919-25-000051 6 15 CF 0 H Increase Decrease In Prepaid Deferred Expense And Other Assets us-gaap/2024 Prepaid expenses and other current assets 1
0002007919-25-000051 6 16 CF 0 H Increase Decrease In Other Noncurrent Assets us-gaap/2024 Other non-current assets 1
0002007919-25-000051 6 17 CF 0 H Increase Decrease In Accounts Payable us-gaap/2024 Accounts payable 0
0002007919-25-000051 6 18 CF 0 H Increase Decrease In Accrued Liabilities us-gaap/2024 Accrued expenses 0

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
report Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site.
line Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived.
stmt The financial statement location to which the value of the “report” field pertains.
inpth Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700.
rfile The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file.
tag The tag chosen by the filer for this line item.
version The taxonomy identifier if the tag is a standard tag, otherwise adsh.
plabel The text presented on the line item, also known as a “preferred” label.
negating Flag to indicate whether the plabel is negating.